Cognitive effects of chemotherapy in breast cancer patients: A dose-response study

Psycho-Oncology

Volumn 22, Issue 7, 2013, Pages 1517-1527

  Collins, Barbara ^a,b   Mackenzie, Joyce ^a   Tasca, Giorgio A ^a,b   Scherling, Carole ^c   Smith, Andra ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

breast cancer; chemotherapy; cognitive changes; dose response relationship; neuropsychological testing; oncology

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MOOD; MULTIPLE CYCLE TREATMENT; NEUROPSYCHOLOGICAL TEST; SCORING SYSTEM; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY;

BREAST CANCER; CHEMOTHERAPY; COGNITIVE CHANGES; DOSE-RESPONSE RELATIONSHIP; NEUROPSYCHOLOGICAL TESTING; ONCOLOGY;

ADOLESCENT; ADULT; AFFECT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; MEMORY; MIDDLE AGED; MULTILEVEL ANALYSIS; NEUROPSYCHOLOGICAL TESTS; QUESTIONNAIRES; YOUNG ADULT;

EID: 84879902138     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3163     Document Type: Article

References (83)

1. Hurricane Voices Breast Cancer Foundation: cognitive changes related to cancer treatment. Available from: http://www.hurricanevoices.org/downloads/hv- cognitive-results.pdf
2. Ahles TA, Saykin AJ, Furstenberg T, et al,. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20: 485-493. DOI: 10.1200/JCO.20.2.485.
3. Ahles TA, Saykin AJ, McDonald BC, et al,. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 2010; 28: 4434-4440. DOI: 10.1200/JCO.2009.27.0827.
4. Bender CM, Sereika SM, Berga SL, et al,. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2006; 15: 422-430. DOI: 10.1002/pon.964.
5. Brezden C, Phillips K-A, Bunston T, Tannock IF,. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-2701.
6. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA,. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004; 26: 955-969. DOI: 10.1080/13803390490510905.
7. de Ruiter MB, Reneman L, Boogerd W, et al,. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011; 32: 1206-1219. DOI: 10.1002/hbm.21102.
8. de Ruiter MB, Reneman L, Boogerd W, et al,. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp epub 2011 September 23. DOI: 10.1002/hbm.21422.
9. Deprez S, Amant F, Smeets A, et al,. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012; 30: 274-281. DOI: 10.1200/JCO.2011.36.8571.
10. Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF,. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 2006; 15: 921-930. DOI: 10.1002/pon.1035.
11. Hurria A, Rosen C, Hudis C, et al,. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006; 54: 925-931. DOI: 10.1111/j.1532-5415.2006.00732.x.
12. Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J,. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psycho-Oncology 2008; 17: 1189-1195. DOI: 10.1002/pon.1342.
13. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA,. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 2011; 19: 1647-1656. DOI: 10.1007/s00520-010-0997-4.
14. Kesler SR, Kent JS, O'Hara R,. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011; 68: 1447-1453. DOI: 0.1001/archneurol.2011.245.
15. Kreukels BP, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB,. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 2008; 8: 80-87. DOI: 10.3816/CBC.2008.n.006.
16. Kvale EA, Clay OJ, Ross-Meadows LA, et al,. Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial. Eur J Cancer Care 2010; 19: 110-117. DOI: 10.1111/j.1365-2354. 2008.01018.x.
17. Mar Fan HG, Houédé-Tchen N, Yi Q-L, et al,. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 31: 8025-8032. DOI: 10.1200/jco.2005.01.6550.
18. Minisini AM, De Faccio S, Ermacora P, et al,. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 2008; 67: 71-79. DOI: 10.1016/j.critrevonc.2008.02.004.
19. Nieuwenhuijsen K, de Boer A, Spelten E, Sprangers MAG, Verbeek JHAM,. The role of neuropsychological functioning in cancer survivors' return to work one year after diagnosis. Psycho-Oncology 2009; 18: 589-597. DOI: 10.1002/pon.1439.
20. O'Shaughnessy JA,. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3: S116-S120.
21. Poppelreuter M, Weis J, Külz AK, Tucha O, Lange KW, Bartsch HH,. Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004; 40: 43-49. DOI: 10.1006/j.ejca.2003.08.001.
22. Quesnel C, Savard J, Ivers H,. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009; 116: 113-123. DOI: 10.1007/s10549-008-0114-2.
23. Reid-Arndt SA, Hsieh C, Perry MC,. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psycho-Oncology 2010; 19: 535-544. DOI: 10.1002/pon.1581.
24. Reid-Arndt SA, Yee A, Perry MC, Hsieh C,. Cognitive and psychological factors associated with early post-treatment functional outcomes in breast cancer survivors. J Psychosoc Oncol 2009; 27: 415-434. DOI: 10.1080/ 07347330903183117.
25. Schagen SB, van Dam F, Muller MJ, Boogerd W, Lindeboom J, Bruning PF,. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650.
26. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FSAM,. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006; 98: 1742-1745. DOI: 10.1093/jnci/djj470.
27. Scherwath A, Mehnart A, Schleimer B, et al,. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006; 17: 415-423. DOI: 10.1093/annonc/mdj108.
28. Schilder CM, Eggens PC, Seynaeve C, et al,. Neuropsychological functioning in post-menopausal breast cancer patients treated with tamoxifen or examestane after AC chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48: 76-85. DOI: 10.1080/02841860802314738.
29. Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D,. The effects of adjuvant chemotherapy on cognition in women with breast cancer-preliminary results of an observational longitudinal study. Breast 2005; 14: 142-150. DOI: 10.1016/j.breast.2004.10.004.
30. Stewart A, Collins B, MacKenzie J, Tomiak E, Verma S, Bielajew C,. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17: 122-130. DOI: 10.1002/pon.1210.
31. Tchen N, Juffs HG, Downie FP, et al,. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21: 4175-4183. DOI: 10.1200/JCO.2003.01.119.
32. van Dam F, Schagen SB, Muller MJ, et al,. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218. DOI: 10.1093/jnci/90.3.210.
33. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G,. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 2009; 15: 951-962. DOI: 10.1017/S1355617709990567.
34. Wagner LI, Sweet JJ, Butt Z, et al,. Trajectory of cognitive impairment during breast cancer treatment: a prospective analysis. J Clin Oncol 2006; 24 (18S): 8500.
35. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 2004; 100: 2292-2299. DOI: 10.1002/cncr.20272.
36. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA,. Acute and late-onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356. DOI: 10.1002/cncr.25098.
37. Weis J, Poppelreuter M, Bartsch HH,. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: subjective complaints and objective neuropsychological test results. Psycho-Oncology 2009; 18: 775-782. DOI: 10.1002/pon.1472.
38. Wienecke MH, Dienst ER,. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4: 61-66. DOI: 10.1002/pon.2960040108.
39. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK,. Neuropsychological outcomes of older breast cancer survivors: cognitive features 10 or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 2010; 22: 48-54. DOI: 10.1176/appi.neuropsych.22.1.48.
40. Ahles TA, Saykin AJ, McDonald BC, et al,. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152. DOI: 10.1007/s10549-007-9686-5.
41. Cimprich B, Ronis DL,. Attention and symptom distress in women with and without breast cancer. Nurs Res 2001; 50: 86-94. DOI: 10.1097/00006199- 200103000-00004.
42. Cimprich B, Reuter-Lorenz P, Nelson J, et al,. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010; 32: 324-331. DOI: 10.1080/13803390903032537.
43. Hermelink K, Untch M, Lux MP, et al,. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109: 1905-1913. DOI: 10.1002/cncr.22610.
44. Meyers CA, Byrne KS, Komaki R,. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995; 12: 231-235.
45. Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A,. Pre-chemotherapy differences in visuo-spatial working memory in breast cancer patients compared to controls: an fMRI study. Front Hum Neurosci 2011; 5: 122. Epub 2011 November 1. DOI: 10.3389/fnhum.2011.00122.
46. Schilder CM, Seynaeve C, Linn SC, et al,. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol 2010; 76: 133-141.
47. Tager FA, McKinley PS, Schnabel FR, et al,. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 2010; 123: 25-34.
48. Wefel JS, Lenzi R, Theriault RL, Buzdar AU, Cruickshank S, Meyers CA,. 'Chemobrain' in breast carcinoma? A prologue. Cancer 2004; 101: 466-475. DOI: 10.1002/cncr.20393.
49. Reddy LH,. Drug delivery to tumors: recent strategies. J Pharm Pharmacol 2005; 57: 1231-1242.
50. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB,. Designing Clinical Research (3rd edn). Lippincott: Williams & Wilkins: Philadelphia, 2007.
51. Kreukels BPC, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FSAM,. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005; 94: 53-61. DOI: 10.1007/s10549-005-7093-3.
52. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, Van Dam FSAM,. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001; 51: 159-165.
53. Brown MS, Simon JH, Stemmer SM, et al,. MR and proton spectroscopy of white matter disease induced by high-dose chemotherapy with bone marrow transplant in advanced breast carcinoma. Am J Neuroradiol 1995; 16: 2013-2020.
54. Brown MS, Stemmer SM, Simon JH, et al,. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol 1998; 19: 217-221.
55. Stemmer SM, Stears JC, Burton BS, Jones RB, Simon JH,. White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. Am J Neuroradiol 1994; 15: 1267-1273.
56. Wechsler D,. Wechsler Adult Intelligence Scale (3rd edn). Harcourt, Brace, & Co: San Antonio, TX, 1997.
57. Army Individual Test Battery. Manual for Directions and Scoring. War Department, Adjutant General's Office: Washington, DC, 1944.
58. Gualtieri CT, Johnson LG,. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol 2006; 21: 623-643. Epub 2006 October 2. DOI: 10.1016/j.acn.2006.05.007.
59. Gualtieri CT, Johnson LG,. A computerized test battery sensitive to mild and severe brain injury. Medscape J Med 2008; 10: 90. Epub 2008 April 15.
60. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G,. Administration and Scoring Manual for the Multiple Sclerosis Functional Composite Measure (MSFC). National Multiple Sclerosis Society: New York, 2001.
61. Rao SM, Leo GJ, Bernardin L, Unverzagt F,. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
62. Brown J,. Some tests of the decay theory of immediate memory. Quart J Exp Psychol 1958; 10: 12-21.
63. Delis DC, Kaplan E, Kramer JH,. Delis Kaplan Executive Function System Test Manual. Psychological Corporation: San Antonio, TX, 2001.
64. Brandt J, Benedict R,. Hopkins Verbal Learning Test-Revised Professional Manual. Psychological Assessment Resources: Lutz, FL, 2001.
65. Benedict R,. Brief Visuospatial Memory Test-Revised Professional Manual. Psychological Assessment Resources: Lutz, FL, 1997.
66. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS, (eds). Neuropsychological Assessment (4th edn). Oxford University Press: New York, NY, 2004.
67. Strauss E, Sherman EMS, Spreen O,. A Compendium of Neuropsychological Tests (3rd edn). Oxford University Press: New York, NY, 2006.
68. Wefel JS, Vardy J, Ahles T, Schagen SB,. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 703-708. Epub 2011 February 25. DOI: 10.1016/S1470-2045(10)70294-1.
69. Beck AT, Steer RA, Brown GK,. Beck Depression Inventory-Second Edition Manual. Psychological Corporation: San Antonio, TX, 1996
70. Bremner JD, Southwick SM, Charney DS,. The neurobiology of posttraumatic stress disorder: an integration of animal and human research. In Posttraumatic Stress Disorder: A Comprehensive Text. Allyn & Bacon: New York, NY, 1999; 103-143.
71. Singer JD, Willett JB,. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. Oxford University Press: New York, NY, 2003.
72. Cohen J,. Statistical Power Analysis for the Behavioral Sciences (2nd edn). Lawrence Erlbaum Associates: Hillsdale, NJ, 1988.
73. Raudenbush SW, Bryk AS, Congdon R,. HLM6: Hierarchical Linear and Nonlinear Modeling [Computer Software]. Scientific Software International: Lincolnwood, IL, 2007.
74. Clegg E,. Chemobrain: How Cancer Therapies Can Affect Your Mind. Prometheus Books: Amherst, NY, 2009.
75. Silverman D, Davidson I,. Your Brain After Chemo. Da Capo Press: Philadelphia, PA, 2009.
76. Boykoff N, Moieni M, Subramanian SK,. Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surv 2009; 3: 223-232. DOI: 10.1007/s11764-009-0098-x.
77. Shilling V, Jenkins V,. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 2007; 11: 6-15.
78. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H,. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008; 8: 88-91.
79. Deprez S, Amant F, Yigit R, et al,. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011; 32: 480-492. DOI: 10.1002/hbm.21033.
80. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA,. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007; 25: 3866-3870. DOI: 10.1200/JCO.2007.10.8639.
81. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M,. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 5: 22.
82. Seigers R, Fardell JE,. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011; 35: 729-741. DOI: 10.1016/j.neubiorev.2010.09.006.
83. Saykin AJ, McDonald B, Ahles TA, et al,. Altered brain activation following systemic chemotherapy for breast cancer: interim analysis from a prospective fMRI study. Poster presented at the 34th Annual Meeting of the International Neuropsychological Society, Boston, MA, February 3, 2006.